Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

WASHINGTON >> U.S. Health Secretary Robert Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...